[MO38] Mini-Oral Session 38　臓器横断プログラム4（第一相試験と遺伝子異常に基づく医療）
【E】

[MO38-2] Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors

^○Kentaro Yamazaki¹, Takayuki Yoshino², Kazunori Honda³, Yasutoshi Kuboki², Takeshi Kawakami¹, Seiichiro Mitani³, Yoshiaki Nakamura², Hiroya Taniguchi³, Hideaki Bando², Tomoyuki Tanaka⁴, Keisuke Tada⁴, Nathalie Fagniez⁵, Kei Muro³ (1.Shizuoka Cancer Center, Shizuoka, Japan, 2.National Cancer Center Hospital East, Chiba, Japan, 3.Aichi Cancer Center Hospital, Aichi, Japan, 4.Sanofi, Tokyo, Japan, 5.Sanofi, Chilly-Mazarin, France)